ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2011
Health care costs and their predictors of inflammatory bowel diseases in Germany.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents.Alimentary pharmacology & therapeutics · 2021Pooled it
- The economic and quality-of-life burden of Crohn's disease in Europe and the United States, 2000 to 2013: a systematic review.Digestive diseases and sciences · 2015Pooled it
- A Care Coordination Intervention Improves Symptoms But Not Charges in High-Risk Patients With Inflammatory Bowel Disease.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022Trial
- Costs of Healthcare for Children with Inflammatory Bowel Diseases (IBD) in Poland.Children (Basel, Switzerland) · 2023Article
- Rates of clinical remission and inadequate response to advanced therapies among patients with ulcerative colitis in Germany.International journal of colorectal disease · 2023Article
- The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe.BMC gastroenterology · 2021Observational
- Prediction of Recurrent Emergency Department Visits among Patients with Crohn's Disease: A Retrospective Study.Journal of clinical medicine · 2020Article
- Article
- Trends and Factors Associated with Hospitalization Costs for Inflammatory Bowel Disease in the United States.Applied health economics and health policy · 2019Article
- Determinants of Healthcare Utilization Among Veterans with Inflammatory Bowel Disease.Digestive diseases and sciences · 2017Article
- Factors That Predict High Health Care Utilization and Costs for Patients With Inflammatory Bowel Diseases.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2017Article
- Differences in the public medical insurance systems for inflammatory bowel disease treatment in Asian countries.Intestinal research · 2016Article
- Article
- Out-of-pocket Cost Burden in Pediatric Inflammatory Bowel Disease: A Cross-sectional Cohort Analysis.Inflammatory bowel diseases · 2015Article
- Nanomedicine delivers promising treatments for rheumatoid arthritis.Nanomedicine (London, England) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesDetailed cost studies of inflammatory bowel diseases (IBD) for Germany are limited. Aim of this study was to collect resource-use data related to IBD via a cross-sectional study, to quantify these from the perspective of the Statutory Health Insurance (SHI) and to identify cost-driving factors.
methodsPatients with Crohn's disease (CD) or ulcerative colitis (UC) from 24 gastroenterological specialists' practices and two hospitals were enrolled in an internet-based database between March 2006 and July 2007. Outpatient services, inpatient visits as well as medication usage were recorded and evaluated from the perspective of the SHI for 2007. Disease severity was measured by the Crohn's Disease Activity Index (CDAI) and the Colitis Activity Index (CAI), respectively. Extensive statistical analyses including generalized linear modeling (gamma model with the log link) to identify cost-driving factors were performed.
resultsData from 1,030 patients with IBD (CD: 511; UC: 519) were collected. On average a patient with CD incurs annual costs of EUR 3,767 (± 5,895 (SD)) (among those 68.5% medication; 20.5% inpatient) and an average patient with UC incurs EUR 2,478 (± 4,591) (74% medication; 10% inpatient), whereas 10% of the patient with IBD account for 49% (CD: 50%; UC: 46%) of the costs. The regression analysis showed that especially the use of TNF-alpha-inhibitors, inpatient stays, gender as well as the severity status has a significant influence on costs. Further disease-specific impact factors were identified.
conclusionsThis is the first study to calculate costs due to CD and UC from the perspective of the SHI in Germany and to identify cost-driving factors. It confirms a high economic burden of IBD to payers and society.
Indexed as
Identifiers
20967482What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.